<--- Back to Details
First PageDocument Content
Rare diseases / Aging / Gerontology / Progeria / Farnesyltransferase inhibitor / Progerin / LMNA / Lonafarnib / Clinical trial / Health / Genodermatoses / Medicine
Date: 2013-08-03 16:03:00
Rare diseases
Aging
Gerontology
Progeria
Farnesyltransferase inhibitor
Progerin
LMNA
Lonafarnib
Clinical trial
Health
Genodermatoses
Medicine

news WWW.PROGERIARESEARCH.ORG • SEPTEMBER, 2012 S P

Add to Reading List

Source URL: www.progeriaresearch.org

Download Document from Source Website

File Size: 2,51 MB

Share Document on Facebook

Similar Documents

PROUD PROUD Participant Involvement meeting: Trial Design Date: Tuesday 9th September – 20.00 Venue: MRC Clinical Trials Unit at UCL, Aviation House, 125 Kingsway, Holborn, WC2B 6NH Contact person: Mitzy Gaf

DocID: 1vq4y - View Document

Clinical Review & Education JAMA | Special Communication Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols

DocID: 1vmrb - View Document

For immediate release March 21, 2017 Infectex Announces Positive Phase 2b-3 Clinical Trial Results of SQ109 for the Treatment of Multidrug-Resistant Pulmonary Tuberculosis Moscow, Russia and Rockville, MD, USA -- Infecte

DocID: 1vkmw - View Document

DEPARTMENT OF HEALTH DRUG OFFICE DRUG REGISTRATION AND IMPORT/EXPORT CONTROL DIVISION Guidance Notes on the Application for Certificate for Clinical Trial/Medicinal Test Background

DocID: 1vkj3 - View Document

CLINICAL TRIAL OUTCOME DATABASE (CTOD) Novartis RA: Longitudinal Model-Based Meta-Analysis in Rheumatoid Arthritis: An Application Toward Model-Based Drug Development Authors I Demin, B Hamren, O Luttringer, G Pillai and

DocID: 1vbDv - View Document